Entry Detail

General Information

Database ID: LDA0006380
Species: Homo sapiens
Confidence Score: 0.731059
Contents: >> ncRNA Information
>> ncRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference
Causality: Yes
Clinical Significance: Unknown

 


ncRNA Information

Reference Genome Note: GRCh38 for human lncRNAs; GRCm39 for mouse lncRNAs; mRatBN7.2 for rat lncRNAs; hg19 for human circRNAs; mm9 for mouse circRNAs.

ncRNA Symbol:SOD2
Full Name:superoxide dismutase 2
Category:LncRNA
Species:Homo sapiens
Synonyms:GC1|GClnc1|IPO-B|IPOB|MNSOD|MVCD6|Mn-SOD
Chromosome:6
Strand:-
Coordinate:
Start Site(bp):159669069End Site(bp):159762281
External Links:
Ensembl ID:ENSG00000291237
Ensembl Transcript ID:N/A
Entrez Gene:6648.0
NONCODE ID:N/A
RefSeq Accession:N/A

 

ncRNA Association Statistics

Total Associated Disease Number:10   
More Information
Causal Disease Number:10
Network:
Top Causal Diseases:
Ovarian Neoplasms  (Score: 0.731059)
Colorectal Neoplasms  (Score: 0.731059)
Carcinoma, Ovarian Epithelial  (Score: 0.731059)
Urinary Bladder Neoplasms  (Score: 0.731059)
Carcinoma, Non-Small-Cell Lung  (Score: 0.731059)
Ovarian Neoplasms  (Score: 0.731059)
Colorectal Neoplasms  (Score: 0.731059)
Carcinoma, Ovarian Epithelial  (Score: 0.731059)
Urinary Bladder Neoplasms  (Score: 0.731059)
Carcinoma, Non-Small-Cell Lung  (Score: 0.731059)
More Information

 

 

Disease Information

 Disease OntologyMeSH
Disease ID:DOID:3908D002289
Disease Name:lung non-small cell carcinomaCarcinoma, Non-Small-Cell Lung
Category:Disease OntologyMeSH
Type:Neoplasms
Define:A lung carcinoma that is characterized as any type of epithelial lung cancer other than small cell lung carcinoma.A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Alias:NSCLC//Non-small cell lung cancer//non-small cell lung carcinomaCarcinoma, Non-Small-Cell Lung//Carcinoma, Non Small Cell Lung//Carcinomas, Non-Small-Cell Lung//Lung Carcinoma, Non-Small-Cell//Lung Carcinomas, Non-Small-Cell//Non-Small-Cell Lung Carcinomas//Non-Small-Cell Lung Carcinoma//Non Small Cell Lung Carcinoma//Carcinoma, Non-Small Cell Lung//Non-Small Cell Lung Carcinoma//Non-Small Cell Lung Cancer//Nonsmall Cell Lung Cancer

 

Disease Association Statistics

Total Associated ncRNA Number:1090   
More Information
Causal ncRNA Number:936
Network:
Top Causal ncRNAs:
AFAP1-AS1  (Score: 1)
FEZF1-AS1  (Score: 1)
BCYRN1  (Score: 1)
GAS5  (Score: 1)
MALAT1  (Score: 1)
MAGI2-AS3  (Score: 1)
AWPPH  (Score: 1)
DANCR  (Score: 1)
hsa_circ_0007385  (Score: 1)
hsa_circ_0074027  (Score: 1)
More Information

 

Evidence Support

Strong Evidence:RNA Pull-Down//Western Blot//Transfection//qPCR//RIP//PCR//IP//IF
Weak Evidence:

 

Reference

[1] PubMed ID:35188072
Disease Name:Carcinoma, Non-Small-Cell Lung
Sample:NSCLC tumor tissues
Dysfunction Pattern:Interaction(miR-2355-5p/CAMSAP2)
Validated Method:RNA Pull-Down//Western Blot//Transfection//qPCR//RIP//PCR//IP//IF
Description: We found elevated expression of circSOD2 and CAMSAP2 while reduced expression of miR-2355-5p in NSCLC tumor tissues. Silencing or overexpression of CircSOD2 resulted in increased or decreased expression of miR-2355-5p, respectively. Mechanically, we showed that silencing of CircSOD2 and overexpression of miR-2355-5p resulted in the reduced rate of NSCLC cell proliferation. Inhibition of miR-2355-5p reversed the changes induced via silencing of CircSOD2. MiR-2355-5p binds to the CircSOD2 promoter and triggered its stimulation, which further activated circSOD2 expression.
Causality:Yes
Causal Description: CircSOD2 suppression impaired lung cancer cell growth, cell migration, prohibited cell cycle progression, and in vivo tumor growth by targeting miR-2355-5p expression in NSCLC tissues. Meanwhile, increased expression of CAMSAP2 reversed the changes stimulated by the elevated level of miR-2355-5p in NSCLC progression.
Clinical-realted Application: